bluuebunny/crossref_metadata_2025_split huggingface dataset:
Abstract B57: A RCT of a community health worker intervention using HPV self-sampling to increase cervical cancer screening among minority populations
Authors: Carrasquillo Olveen , Koru-Sengul Tulay , McCann Sheila , Amofah Anthony , Kobetz Erin 
Published: May 2015

Abstract
Background: Caribbean immigrants (both Hispanics and Blacks from Haiti) are less likely to be screened for cervical cancer than the general population. One promising approach is outreach strategies that employ Community Health Workers (CHWs). Yet even in well structured CHW programs, many women remain unscreened. In our NCI Community Networks sponsored project, we are testing an approach that combines CHWs with self sampling for the human papilloma virus (HPV) as a screening strategy among such hard to reach populations.
Methods: Using a community based participatory research framework, community we are enrolling 600 Latina, Haitian and African American women ages 30-65 who have not had a Pap smear in the 3 last years into a randomized study. health workers (CHWs). Group one receives culturally tailored CHW led public health outreach and education. Groups 2 and 3 receive a one hour CHW home health education session and individualized navigation by the CHWs to Pap smear screening at community based facilities. Women in group 3 have the option of Pap smear or HPV self sampling. A research assistant blinded to study allocation performs a 6 month follow-up assessment.
Results: In 20 months, CHWs have assessed over 3,000 women for study inclusion. One quarter have been study eligible and we have randomized 417 such women, approximately 40% Hispanic, 40% Haitian and 80% African American. To date, have analyzed 6 month follow-up data on 217 women. Among women randomized to culturally tailored health outreach, 32% reported having had a Pap smear at 6 months. In group 2, 54% have been screened. In groups 3, 87% have been screened. Among women in Group 3 to whom we offered HPV self-sampling or tailored navigation to a Pap Smear, 73% preferred to perform HPV self-sampling.
Conclusions: Using the CBPR framework, we have randomized nearly 70% of our planned “hard to reach” study population into our RCT. Our preliminary data suggest that tailored health outreach and individualized CHW navigation are highly effective. Our data, also make an extremely strong case for HPV self-sampling as a strategy for screening among unscreened minority women.
Citation Format: Olveen Carrasquillo, Tulay Koru-Sengul, Sheila McCann, Anthony Amofah, Erin Kobetz. A RCT of a community health worker intervention using HPV self-sampling to increase cervical cancer screening among minority populations. [abstract]. In: Proceedings of the Sixth AACR Conference: The Science of Cancer Health Disparities; Dec 6–9, 2013; Atlanta, GA. Philadelphia (PA): AACR; Cancer Epidemiol Biomarkers Prev 2014;23(11 Suppl):Abstract nr B57. doi:10.1158/1538-7755.DISP13-B57
Abstract B92: HPV and Pap test results among low-income, underserved women: Providing insights into management strategies
Authors: Saraiya Mona , Benard Vicki , Greek April , Steinau Martin , Patel Sonya , Manninen Diane , Sawaya George , Massad Stuart , Unger Elizabeth 
Published: May 2015

Abstract
Objective: Human papillomavirus (HPV) DNA testing combined with cytology (co-testing) has been recommended as a primary cervical cancer screening strategy and will be covered as a preventive service by the Affordable Care Act (ACA). Women with discordant results (HPV positive/cytology negative) present significant management challenges and result in additional costs due to follow-up visits and testing required. The frequency of discordant results in insured populations is at a level that does not negate the benefit of co-testing. However, it is unknown if the frequency of discordant results would be the same for underserved women, who may have more risk factors for HPV infection and cancer precursors.
Methods: The Centers for Disease Control and Prevention's Cervical Cancer (Cx3) Study was conducted at 15 clinics in 6 Federally Qualified Health Centers (FQHCs) across Illinois. Providers at these clinics were given the option of co-testing for routine cervical cancer screening. Clinical high-risk HPV testing was performed using the FDA approved Hybrid Capture 2 assay (HC2: Qiagen). An additional research test to determine type-specific HPV results was performed on residual extracts.
Results: Testing was completed on 2246 underserved women, mean age 45.1 years. The HPV test was positive in 7.2% and cytology abnormalities were detected in 6.0% with discordant results in 4.9% of women. The percentage of HPV positive tests decreased with age, from 10.3% among 30-39 year olds to 4.5% among 50-60 year olds. Among women with negative normal Pap test results who where high risk positive, 14% of the women were positive for HPV 16/18 while the remaining were positive for other high risk types.
Conclusion: The rate of discordant co-testing in this study of underserved women was similar to those reported throughout the U.S. in different populations, including those who are insured. Similarly, the lower percentage of discordant results and those positive for HPV 16/18 may favor a more conservative management strategy than an aggressive strategy of immediate colposcopy.
Citation Format: Mona Saraiya, Vicki Benard, April Greek, Martin Steinau, Sonya Patel, Diane Manninen, George Sawaya, Stuart Massad, Elizabeth Unger. HPV and Pap test results among low-income, underserved women: Providing insights into management strategies. [abstract]. In: Proceedings of the Sixth AACR Conference: The Science of Cancer Health Disparities; Dec 6–9, 2013; Atlanta, GA. Philadelphia (PA): AACR; Cancer Epidemiol Biomarkers Prev 2014;23(11 Suppl):Abstract nr B92. doi:10.1158/1538-7755.DISP13-B92
Abstract C15: Inflammation-free survival as a surrogate endpoint for overall survival in patients with metastatic renal cell carcinoma
Authors: Harris Wayne B. , Nickleach Dana C. , Liu Yuan , Kucuk Omer , Master Viraj A. 
Published: May 2015

Abstract
Background: The primary objective of the present study was to determine the degree to which factors other than race or ethnicity contribute to large disparities in clinical outcome for patients treated with targeted therapy for metastatic renal cell carcinoma (mRCC).
Methods: A single institution retrospective study was conducted at the Winship Cancer Institute of Emory University. Inclusion criteria were as follows: (1) diagnosis of mRCC, (2) treatment with at least 1 targeted agent for mRCC and (3) concurrent serum C-reactive protein and albumin levels on at least 3 occasions that were at least 2 weeks apart. Statistical analysis was conducted using SAS V9.3 and R2.15.2. Kinetic risk assessment was performed with the newly devised inflammation intensity index (I3). Univariate and multivariate analyses were also completed.
Results: The median overall survival (OS) for the entire cohort (n=55) was 30.6 months (95% CI 19.8, 49.4) with a median follow up of 27.1 months (95% CI 22.0, 31.3). The median OS for non-Hispanic whites (n=39) was 38.4 months (95% CI 23.7, 49.4) vs. 8.6 months (95% CI 5.0, 25.6) for African Americans (n=14) and Hispanics (n=2) with a log-rank p value of &lt;0.0001. Multivariate analysis demonstrated OS was most closely associated with kinetic risk as defined by the I3 risk assessment tool (type 3 p value &lt;0.001) and nephrectomy status (type 3 p value 0.010), but not race/ethnicity.
Conclusions: Prolonged OS was most closely associated with persistent inflammation free survival and shorter OS with increases in the intensity and duration of systemic inflammation.
Citation Format: Wayne B. Harris, Dana C. Nickleach, Yuan Liu, Omer Kucuk, Viraj A. Master. Inflammation-free survival as a surrogate endpoint for overall survival in patients with metastatic renal cell carcinoma. [abstract]. In: Proceedings of the Sixth AACR Conference: The Science of Cancer Health Disparities; Dec 6–9, 2013; Atlanta, GA. Philadelphia (PA): AACR; Cancer Epidemiol Biomarkers Prev 2014;23(11 Suppl):Abstract nr C15. doi:10.1158/1538-7755.DISP13-C15
Abstract C34: Comparing patient navigation and survivorship care plans: How do they relate to healthcare among Hispanic and non-Hispanic cancer survivors?
Authors: Jabson Jennifer M. 
Published: May 2015

Abstract
Purpose: Patient navigation (PN), and survivorship care plans, including follow-up care instructions (FCI) and treatment summaries (TS), have been mandated by national organizations as a strategy to improve healthcare received by cancer survivors, and to reduce disparities among survivor subgroups. Empirical evidence has linked PN, FCI, and TS, with survivors' receipt of cancer-related healthcare including cancer surveillance, cancer screenings, and attendance at medical appointments. However, it is currently unknown if these strategies relate equivalently to receipt of healthcare among ethnically diverse survivors, or if one strategy is more important than another.
Methods: Using data from the 2010 LIVESTRONG online survey of cancer survivors (N=4286), the current study tested the associations between FCI, TS, PN and receipt of cancer surveillance, cancer screening, and attendance at regular medical appointments. Analyses were stratified by survivor ethnicity.
Results: In the full sample, FCI related to attendance at regular medical appointments (OR 1.50, 95% CI 1.07, 2.10), cancer surveillance (OR 1.49 95%CI 1.16, 1.93), and cancer screening (OR 2.40 95%CI 1.80, 3.21). PN was related to attendance at medical appointments (OR 1.50 95%CI 1.07, 2.10) and cancer screening (OR 1.31 95%CI 1.03, 1.67). TS related to attendance at medical appointments (OR 1.48 95%CI 1.07, 2.06). Associations varied by survivor ethnicity. Among non-Hispanic white survivors FCI related to all cancer-related healthcare outcomes, and TS related to attendance at medical appointments. Among Hispanic survivors, FCI related to cancer surveillance (OR 3.52 95%CI 1.12, 1.96).
Conclusions: FCI were consistently associated with survivors' cancer-related healthcare. However, FCI, TS, and PN were not equally associated with cancer-related healthcare for all cancer survivors. This evidence suggests that FCI is a valuable strategy for ensuring survivors receipt of cancer-related healthcare, and this may be especially true for Hispanic survivors' receipt of cancer surveillance.
Citation Format: Jennifer M. Jabson. Comparing patient navigation and survivorship care plans: How do they relate to healthcare among Hispanic and non-Hispanic cancer survivors?. [abstract]. In: Proceedings of the Sixth AACR Conference: The Science of Cancer Health Disparities; Dec 6–9, 2013; Atlanta, GA. Philadelphia (PA): AACR; Cancer Epidemiol Biomarkers Prev 2014;23(11 Suppl):Abstract nr C34. doi:10.1158/1538-7755.DISP13-C34
Abstract C39: Docetaxel-induced growth and cell cycle phenotypes in prostate stromal cells
Authors: Gales Dominique , McMcmeans Brionna , Samuel Temesgen 
Published: May 2015

Abstract
Background: Docetaxel (D) is a clinically used front-line chemotherapeutic agent for castration resistant advanced prostate cancer. However, its long-term benefits are limited with most patients eventually progressing because of inherent or acquired drug resistance. The treatment of advanced prostate cancer is a significant challenge and there are no effective treatments that stably suppress the disease. The mechanisms behind resistance to Docetaxel are not fully understood.
Since in vivo Docetaxel cytotoxicity is directed not only to cancer cells, we hypothesize that the response of prostate stromal cells exposed to chemotherapeutic agents could modify drug response or therapeutic outcome in prostate cancer. One of cellular responses to chemotherapy is NF-kB activation and inflammatory signaling. NF-κB activation has been proposed as an important event in PCa development, castration-resistant progression and resistance to chemotherapy.
Objective: In this study, we examined the response of prostate stromal (WPMY- 1) cells to Docetaxel.
Current Results: Cellular proliferation was analyzed by MTT assay. The IC50 of Docetaxel for WPMY-1 cells was 10nM. Cell cycle profiles were assessed by flow cytometry. The analysis showed that Docetaxel (10-100nM) induced prominent G2-M arrest in these stromal cells within 24 hours, especially in the higher dose ranges. Interestingly lower doses of Docetaxel (10nM), in contrast to higher doses, consistently resulted in accumulation of sub-G1 population (28% 10nM vs 6% in 100nM) of cells suggestive of fragmented DNA associated with apoptotic process. We show that Docetaxel exhibits strong anti-proliferative effects on prostate stromal WPMY-1 cells.
Conclusions: These preliminary results show that stromal cells are sensitive to Docetaxel. Why lower doses of the drug induce sub-G1 (apoptotic) accumulation while higher doses preferentially induce G2-M arrest is currently unknown.
Future Steps: We will compare responses to D between prostate cancer cells and stromal cells in individual and co-culture models. NF-kB activity following D treatment or radiation, and the expression of genes in NF-kB pathway in D treated cells will be examined.
Citation Format: Dominique Gales, Brionna McMcmeans, Temesgen Samuel. Docetaxel-induced growth and cell cycle phenotypes in prostate stromal cells. [abstract]. In: Proceedings of the Sixth AACR Conference: The Science of Cancer Health Disparities; Dec 6–9, 2013; Atlanta, GA. Philadelphia (PA): AACR; Cancer Epidemiol Biomarkers Prev 2014;23(11 Suppl):Abstract nr C39. doi:10.1158/1538-7755.DISP13-C39
Abstract C51: In vitro cytotoxicity of 3-arylcoumarin derivatives in human prostate (PC3) cancer cell line
Authors: Musa Musiliyu A. , Joseph Moise Y. , Latinwo Lekan M. , Badisa Veera L. 
Published: May 2015

Abstract
Coumarins are classified as a member of the benzopyrone family of compounds with diverse and interesting biological activities. They have been used as therapeutic agents in the treatment of various diseases. In the present study, we evaluated the in vitro cytotoxic activity of 3-arylcoumarins (1-11) in human prostate (PC3) cancer and (WPE1-NA22) normal cell lines at various concentrations (0, 10, 25, 50, 75 and 100 μM) after 48 h treatment using crystal violet dye binding assay. The most active compounds cytotoxicity was examined by cell cycle analysis, reactive oxygen species (ROS) production, mitochondrial membrane potential (MMP) measurement and Bax protein expression. Our findings indicate Result that 8-(acetyloxy)-3-(4-methanesulfonylphenyl)-2-oxo-2H-chromen-7-ylacetate (11) showed cytotoxic activity in PC3 cancer cell line (LD50 = 35.0 μM) and no cytotoxic activity in WPE1-NA22 normal cell line (inactive; LD50 = &gt;100 μM) in comparison to the other synthesized analogs. Furthermore, It caused significant cells arrest (p&lt;0.05) in –G1 phase, increase in ROS production, loss of MMP and increase (up-regulation) of Bax protein expression. These findings suggest that these compounds could serve as new leads for the development of novel synthetic compounds with enhanced anticancer activity.
Grant Support: Research supported by Florida A & M University Title III Program
Citation Format: Musiliyu A. Musa, Moise Y. Joseph, Lekan M. Latinwo, Veera L. Badisa. In vitro cytotoxicity of 3-arylcoumarin derivatives in human prostate (PC3) cancer cell line. [abstract]. In: Proceedings of the Sixth AACR Conference: The Science of Cancer Health Disparities; Dec 6–9, 2013; Atlanta, GA. Philadelphia (PA): AACR; Cancer Epidemiol Biomarkers Prev 2014;23(11 Suppl):Abstract nr C51. doi:10.1158/1538-7755.DISP13-C51
Abstract C52: Associations between religion-related factors and breast cancer screening among American Muslims
Authors: Padela Aasim I. , Murrar Sohad , Adviento Brigid , Hosseinain Zahra , Peek Monica , Olopade Olufunmilayo , Curline Farr 
Published: May 2015

Abstract
Background: The limited research of breast cancer screening among different American Muslim groups consistently demonstrates low rates of mammography. There has been no survey of how religion-related factors influence screening patterns in a diverse sample of American Muslims.
Methods: We partnered with the Council of Islamic Organizations of Greater Chicago to survey English-speaking women aged 40 years and older frequenting mosques and community sites. The self-administered survey included several adapted measures of religiosity, fatalism, and discrimination from the literature, and incorporated a pilot measure of Islamic modesty.
Results: 240 women completed the survey with nearly equal numbers of indigenous African Americans (27%), Arab Americans (33%), and South Asians (32%). 77% of the sample reported ever having a mammogram while only 37% had a mammogram within the past 1-2 years. There were no significant differences in rates by race/ethnicity. On multivariate analysis positive religious coping (OR= 0.21, p &lt;0.05) and perceived religious identity-directed discrimination (OR=0.74, p&lt;0.05) were negatively associated with having biennial mammograms, while having a primary care physician (OR=20, p&lt;0.01,) greatly increased the odds of having a mammogram. Ever having a mammogram was positively associated with years of US residence (&gt;20 yrs OR=4.3, p&lt;0.05) and increasing level of educational attainment. Islamic modesty, fatalistic beliefs, breast cancer knowledge, educational attainment, insurance status and were not associated with mammography rates.
Conclusions: Cancer disparity research typically focuses on inequities across ethnic and racial lines, and therefore overlooks the influence of a shared religion upon health behaviors across race and ethnicity. Our survey suggests that religion-related factors such as positive religious coping and perceived religious discrimination influence breast cancer screening patterns among American Muslims. Consequently, programs leveraging shared religious networks, such as mosques and Imams, may be a means to address religious barriers that impede screening across ethnic and racial lines.
Citation Format: Aasim I. Padela, Sohad Murrar, Brigid Adviento, Zahra Hosseinain, Monica Peek, Olufunmilayo Olopade, Farr Curline. Associations between religion-related factors and breast cancer screening among American Muslims. [abstract]. In: Proceedings of the Sixth AACR Conference: The Science of Cancer Health Disparities; Dec 6–9, 2013; Atlanta, GA. Philadelphia (PA): AACR; Cancer Epidemiol Biomarkers Prev 2014;23(11 Suppl):Abstract nr C52. doi:10.1158/1538-7755.DISP13-C52
Abstract C68: Global transcriptome sequencing of ethnically diverse formalin-fixed patient samples identifies biomarkers of recurrence in prostate cancer
Authors: Xu Jianpeng , Long Qi , Osunkoya Adeboye O. , Sannigrahi Soma , Johnson Brent A. , Zhou Wei , Gillespie Theresa , Park Jong Y. , Nam Robert K. , Sugar Linda , Stanimirovic Aleksandra , Seth Arun K. , Petros John A. , Moreno Carlos S. 
Published: May 2015

Abstract
Prostate cancer remains the second leading cause of cancer death in American men, but biomarkers that can predict outcome following treatment are urgently needed to identify patients with aggressive disease. In an effort to identify biomarkers of recurrence, we have performed global RNA-sequencing on 106 formalin-fixed, paraffin-embedded (FFPE) prostatectomy samples from 100 patients at three independent sites, and identified a new set of biomarkers of biochemical recurrence composed of a 24-gene panel including 22 protein-coding genes and two non-coding genes. We observed excellent correlation between TaqMan and RNAseq values, as well as for RNAseq between replicate libraries. We validated this 24-gene panel on an independent publicly available dataset of 140 patients and this new panel outperformed previously published markers based on cell proliferation gene sets. In addition, we have identified genes that are differentially expressed between African-American and Caucasian prostate cancer patients, and mitochondrial SNPs that are associated with both race and outcome. We observed a number of genes relevant to prostate cancer biology including ETV5, ZEB1, ZEB2, B2M, FYN, and miR-183 that were differentially expressed between African-American and Caucasian patients. These genes may play a role in the disparities observed in African-American patients who have significantly worse outcomes relative to Caucasian patients with prostate cancer.
Citation Format: Jianpeng Xu, Qi Long, Adeboye O. Osunkoya, Soma Sannigrahi, Brent A. Johnson, Wei Zhou, Theresa Gillespie, Jong Y. Park, Robert K. Nam, Linda Sugar, Aleksandra Stanimirovic, Arun K. Seth, John A. Petros, Carlos S. Moreno. Global transcriptome sequencing of ethnically diverse formalin-fixed patient samples identifies biomarkers of recurrence in prostate cancer. [abstract]. In: Proceedings of the Sixth AACR Conference: The Science of Cancer Health Disparities; Dec 6–9, 2013; Atlanta, GA. Philadelphia (PA): AACR; Cancer Epidemiol Biomarkers Prev 2014;23(11 Suppl):Abstract nr C68. doi:10.1158/1538-7755.DISP13-C68
Abstract C72: Estradiol-ERβ signaling axis in disparity of prostate cancer in African American men
Authors: Elmageed Zakaria Y. Abd , Kim Hogyoung , Thomas Raju , Moparty Krishnarao , Abdel-Mageed Asim B. 
Published: May 2015

Abstract
Our study showed that high circulating estrogens and estrogen receptor beta (ERβ) may be implicated in prostate cancer (PCa) progression, and had higher expression level in African American (AA) than Caucasian American (CA) men. However, the underlying mechanisms remain elusive. The objective of this study was to investigate the signaling cross-talk between ERβ; and AR in vitro and in vivo levels. Prostate cancer cells; LNCaP, C4-2B and PC3 were treated with different concentrations and at different time points with 17β-Estradiol (E2) and 5α-dihydrotestosterone (DHT) and examined for cell proliferation by WST assay, promoter activity by luciferase assay, DNA-protein interaction by electrophoretic mobility shift assay (EMSA) and chromatin immunoprecipitation (ChIP) assay. After E2 or DHT treatment, the translocation of ERβ; and AR in PCa cells was also examined using fluorescence microscope.
Our results show that ERβ; was stimulated by treatment of cells with 10nM DHT and AR was also induced by treating PCa cells with10nM E2. These results were confirmed by promoter activity of truncated psPSA-luc in either PCa cell lines or Cos-7 cells. The predesigned Androgen Response Element (ARE) was bound to the protein's receptor after E2 induction. ChIP experiment corroborated the cross-talk between AR and ERβ; after treating C4-2B cells with 10nM E2 for 30 min up to 1.5 hr. Immunofluorescence depicted colocalization of AR and ERβ; in the nucleus after 30 min from E2 treatment. To our knowledge, this is the first report demonstrating crosstalk between ERβ; and AR signaling in PCa in response to E2 treatment. Our results implicate potential therapeutic application by targeting AR and ERβ; in castration-resistant PCa (CRPC).
Citation Format: Zakaria Y. Abd Elmageed, Hogyoung Kim, Raju Thomas, Krishnarao Moparty, Asim B. Abdel-Mageed. Estradiol-ERβ signaling axis in disparity of prostate cancer in African American men. [abstract]. In: Proceedings of the Sixth AACR Conference: The Science of Cancer Health Disparities; Dec 6–9, 2013; Atlanta, GA. Philadelphia (PA): AACR; Cancer Epidemiol Biomarkers Prev 2014;23(11 Suppl):Abstract nr C72. doi:10.1158/1538-7755.DISP13-C72